ClinicalTrials.gg
RecruitingNCT06857214Updated Jul 10, 2026

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

A Phase 1 interventional study of GNC-038 and Belimumab in Systemic Lupus Erythematosus, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
77th of 245
84 · median 36
Started
2025
with 61 others
Phase 1
109 of 266
85 open now
Primary completion
2027-12
later than 127 of 190 live
Registered
157th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 77th largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 109 in phase 1, reaches primary completion later than 127 of the 190 other live ones, and was the 157th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus erythematosus.

Read the detailed description

This study is divided into Phase Ia and Phase Ib studies. The Phase Ia study adopts a single-arm design, while the Phase Ib study will be conducted on the basis of the Phase Ia study and features an open-label, randomized, active-controlled design, with belimumab as the control agent.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects can understand the form, voluntarily participate in and sign the informed consent form;
  2. No gender limit;
  3. Age: ≥18 years old and ≤75 years old;
  4. greater than 6 months;
  5. SLE was diagnosed according to the 2019 EULAR/ACR revised criteria;
  6. Patients with moderate to severe systemic lupus erythematosus, SLEDAI-2K score \&gt at screening; 7 points;
  7. A stable standard-of-care regimen was maintained for at least 30 days before the first dose;
  8. ANA ≥ 1:80 or anti-dsdna antibody higher than the (ULN) as determined by central laboratory at screening;
  9. The presence of CD19+ B cells in the peripheral blood of the patient;
  10. The organ function level before the first administration met the requirements;
  11. Female subjects of or male subjects with a fertile partner must use highly effective from 7 days before the first dose until 24 weeks after the termination of treatment and should commit not to donate eggs (eggs, oocytes)/sperm for assisted reproduction for 1 year after the last study treatment. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
  12. Participants were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Severe lupus nephritis within 8 weeks before screening;
  2. She had uncontrolled lupus crisis within 8 weeks before screening and was not suitable for the study as assessed by the investigator;
  3. Active encephalopathy or psychosis within 6 months before screening;
  4. Primary diagnosis of different or inflammatory diseases;
  5. B cell-depleting therapy within 6 months before initiation of GNC-038 treatment;
  6. Received CAR-T therapy within 6 months before GNC-038 treatment;
  7. Cytokine-targeting biologic agents used within 12 weeks before dose administration;
  8. Use of anti-tumor necrosis factor drugs within 8 weeks before administration;
  9. Use of any JAK inhibitor within 2 weeks before dosing;
  10. Receipt of any drug within 28 days before dose or within 5 half-lives of the investigational drug;
  11. Major organ transplantation history or hematopoietic stem cell/bone marrow transplantation;
  12. Presence of: 1) active at screening; 2) or infection; 3) syphilis infection;
  13. A history of any cardiovascular disease described in the protocol within 6 months before screening;
  14. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
  15. Prolonged at rest (QTcf > 450 msec in men or > 470 msec in women);
  16. A history of ≥ grade 2 bleeding within 30 days before screening or the need for long-term continuous anticoagulant therapy;
  17. Patients with a history of allergy to recombinant humanized antibodies or to any of the of GNC-038;
  18. Women who are pregnant or breastfeeding;
  19. Have a history or evidence of suicidal thoughts within 6 months before signing ICF, which is considered by the researcher to be a significant risk of suicide;
  20. Diagnosed with malignant tumor within 5 years before signing ICF;
  21. Other situations of poor compliance, unwillingness or inability to comply with the study protocol as judged by the investigator;
  22. History of splenectomy;
  23. Investigators considered a history of alcohol or drug abuse in the 12 months before screening;
  24. Any active infection requiring systemic antibiotic treatment within 2 weeks before or during screening;
  25. A history of severe and/or disseminated viral infection;
  26. Active M. tuberculosis infection may be present.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    GNC-038

    Participants receive GNC-038 in the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: GNC-038

  • Active comparator
    Belimumab

    The control group will be set up in phase Ib, participants will receive Belimumab.

    Drug: Belimumab

Interventions

  • Administration by intravenous infusion. Once a week (IV, QW), twice in total.

  • The first 3 doses are administered once every 2 weeks; starting from the 4th dose, once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Dose limiting toxicity (DLT)

    DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.

    Time frame: Up to approximately 28 days

  2. Phase Ia: Maximum tolerated dose (MTD)

    MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.

    Time frame: Up to approximately 28 days

  3. Phase Ia: Treatment-Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-038. The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-038.

    Time frame: Up to approximately 24 months

  4. Phase Ia: Cmax

    Maximum serum concentration (Cmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  5. Phase Ia: Tmax

    Time to maximum serum concentration (Tmax) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  6. Phase Ia: T1/2

    Half-life (T1/2) of GNC-038 will be investigated.

    Time frame: Up to approximately 24 months

  7. Phase Ia: AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  8. Phase Ia: CL (Clearance)

    CL in the serum of GNC-038 per unit of time will be investigated.

    Time frame: Up to approximately 24 months

  9. Phase Ib: Recommended Phase II Dose (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-038.

    Time frame: Up to approximately 24 months

  10. Phase Ib: SRI-4 response rate

    SRI-4 response rate will be investigated.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Anti-drug antibody (ADA)

    Frequency of anti-GNC-038 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

  2. Phase Ia: Receptor Occupancy (RO)

    Receptor Occupancy (RO) will be investigated.

    Time frame: Up to approximately 24 months

  3. Phase Ib: Change from baseline in SLEDAI-2K

    Change from baseline in SLEDAI-2K will be investigated.

    Time frame: Up to approximately 24 months

  4. Phase Ib: Changes in Quality of Life (SF-36)

    Changes in Quality of Life (SF-36) will be investigated.

    Time frame: Up to approximately 24 months

  5. Phase Ib: Proportion of subjects achieving Lupus Low Disease Activity Status (LLDAS)

    Proportion of subjects achieving Lupus Low Disease Activity Status (LLDAS) will be investigated.

    Time frame: Up to approximately 24 months

  6. Phase Ib: Proportion of subjects achieving disease remission (DORIS)

    Proportion of subjects achieving disease remission (DORIS) will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Shuang Ye · Contact
    • Shuang Ye · Principal investigator
    • Qiong Fu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 30 months is close to that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 4, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06857214
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Jun 4, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emfizatamab

Start the discussion